ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,021 to 1,040 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Randomized Sibutramine vs Randomized Placebo: Risk of Death From Any Cause (All-cause Mortality)418 of 4,906

404 of 4,898

0.3 points

-0.8 to 1.4

9,804NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE11 of 4,906

7 of 4,898

0.1 points

-0.1 to 0.3

9,804NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a POE or a Revascularization Procedure927 of 4,906

856 of 4,898

1.4 points

-0.1 to 2.9

9,804NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Vitamins vs Placebo: Admission to NICU577 of 4,900

557 of 4,881

0.4 points

-0.9 to 1.6

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Small for Gestational Age133 of 4,900

132 of 4,881

0.0 points

-0.6 to 0.7

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Birth Weight <2500 Grams345 of 4,900

369 of 4,881

-0.5 points

-1.6 to 0.5

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Respiratory Distress Syndrome150 of 4,900

144 of 4,881

0.1 points

-0.6 to 0.8

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Retinopathy of Prematurity19 of 4,900

16 of 4,881

0.1 points

-0.2 to 0.3

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Apgar Score <=3 at 5 Minutes23 of 4,900

27 of 4,881

-0.1 points

-0.4 to 0.2

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Sepsis30 of 4,900

23 of 4,881

0.1 points

-0.2 to 0.4

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Necrotizing Enterocolitis10 of 4,900

14 of 4,881

-0.1 points

-0.3 to 0.1

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Intraventricular Hemorrhage, Grade III or IV6 of 4,900

7 of 4,881

-0.0 points

-0.2 to 0.1

9,781NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Xylitol vs Control: Number of Infants With Adverse Neonatal Composite Morbidity and Mortality133 of 4,349

238 of 5,321

-1.4 points

-2.2 to -0.7

9,670NCT02333227

Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi

Xylitol vs Control: Rate of Preterm Birth549 of 4,349

878 of 5,321

-3.9 points

-5.3 to -2.5

9,670NCT02333227

Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi

Tamoxifen Followed by Exemestane vs Exemestane: serious adverse events784 of 4,814

831 of 4,852

-0.8 points

-2.3 to 0.6

9,666NCT00036270

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Oral Semaglutide vs Placebo: Number of Participants From Randomization to First Occurrence of CV Death;Renal Death;Onset of Persistent≥50% Reduction in eGFR(CKD-EPI);Onset of Persistent eGFR(CKD-EPI)<15 mL/Min/1.73m^2;Initiation of Chronic Renal Replacement Therapy403 of 4,825

435 of 4,825

-0.7 points

-1.8 to 0.5

9,650NCT03914326

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Oral Semaglutide vs Placebo: Number of Participants From Randomization to First Occurrence of Major Adverse Limb Events (MALE), a Composite Endpoint Consisting of: Acute Limb Ischemia Hospitalisation/Chronic Limb Ischemia Hospitalisation71 of 4,825

99 of 4,825

-0.6 points

-1.1 to -0.1

9,650NCT03914326

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Oral Semaglutide vs Placebo: Number of Participants From Randomisation to First Occurrence of Onset of Persistent eGFR (CKD-EPI) Below 15 mL/Min/1.73 m^223 of 4,825

33 of 4,825

-0.2 points

-0.5 to 0.1

9,650NCT03914326

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Oral Semaglutide vs Placebo: Number of Participants From Randomisation to First Occurrence of Non-fatal Myocardial Infarction (MI)191 of 4,825

253 of 4,825

-1.3 points

-2.1 to -0.4

9,650NCT03914326

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Oral Semaglutide vs Placebo: Number of Participants From Randomisation to Time to Occurrence of Renal Death1 of 4,825

7 of 4,825

-0.1 points

-0.3 to -0.0

9,650NCT03914326

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=52

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00234832-2f5415ed",
        "title": "Randomized Sibutramine vs Randomized Placebo: Risk of Death From Any Cause (All-cause Mortality)",
        "summary": "418 of 4906 against 404 of 4898; risk difference 0.3 points, 95% interval -0.8 to 1.4; NCT00234832, A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients",
        "record": "/library/comparisons/NCT00234832-2f5415ed",
        "nct_id": "NCT00234832",
        "kind": "outcome",
        "participants": 9804,
        "risk_difference": {
          "value": 0.002719147744022904,
          "lower": -0.008266574108377106,
          "upper": 0.013707500572164159
        },
        "group_1": "418 of 4,906",
        "group_2": "404 of 4,898",
        "difference": "0.3 points",
        "interval": "-0.8 to 1.4",
        "trial_title": "A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients"
      },
      {
        "id": "NCT00234832-8cc22a69",
        "title": "Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE",
        "summary": "11 of 4906 against 7 of 4898; risk difference 0.1 points, 95% interval -0.1 to 0.3; NCT00234832, A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients",
        "record": "/library/comparisons/NCT00234832-8cc22a69",
        "nct_id": "NCT00234832",
        "kind": "outcome",
        "participants": 9804,
        "risk_difference": {
          "value": 0.0008129977093240216,
          "lower": -0.0009992351119284368,
          "upper": 0.002728870561461914
        },
        "group_1": "11 of 4,906",
        "group_2": "7 of 4,898",
        "difference": "0.1 points",
        "interval": "-0.1 to 0.3",
        "trial_title": "A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=53",
  "request_id": "4-K_CPHpIl0QaWwN"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?